Data gathered: October 18
Alternative Data for Biomarin Pharmaceutical
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 98 | Sign up | Sign up | Sign up |
| Sentiment | 58 | Sign up | Sign up | Sign up |
| Webpage traffic | 78,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 75 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2,655 | Sign up | Sign up | Sign up |
| Facebook Followers | 7,130 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 33 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,241 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,970 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 35 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,111 | Sign up | Sign up | Sign up |
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Price | $53.29 |
| Target Price | Sign up |
| Volume | 1,760,000 |
| Market Cap | $10.2B |
| Year Range | $52.32 - $72.83 |
| Dividend Yield | 0% |
| PE Ratio | 15.66 |
| Analyst Rating | 85% buy |
| Industry | Biotechnology |
In the news
 |
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts?October 7 - Yahoo |
|
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockOctober 5 - Yahoo |
 |
Lbp Am Sa Lowers Stock Holdings in BioMarin Pharmaceutical Inc. $BMRNOctober 4 - ETF Daily News |
|
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by GAMMA Investing LLCOctober 3 - ETF Daily News |
|
Financial Survey: Arcutis Biotherapeutics (NASDAQ:ARQT) vs. BioMarin Pharmaceutical (NASDAQ:BMRN)October 2 - ETF Daily News |
|
Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story?October 2 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 825M | 150M | 675M | 241M | 307M | 1.440 |
| Q1 '25 | 745M | 152M | 594M | 186M | 224M | 1.130 |
| Q4 '24 | 738M | 136M | 602M | 125M | 196M | 0.920 |
| Q3 '24 | 746M | 188M | 557M | 106M | 156M | 0.550 |
| Q2 '24 | 709M | 145M | 564M | 107M | 162M | 0.560 |
Insider Transactions View All
| Burkhart Erin filed to sell 14,173 shares at $59.3. May 20 '25 |
| Hubbard Cristin filed to sell 32,700 shares at $64.9. May 6 '25 |
| Burkhart Erin filed to sell 16,955 shares at $71.5. March 20 '25 |
| Guyer Charles Greg filed to sell 87,655 shares at $71.3. March 7 '25 |
| Burkhart Erin filed to sell 13,105 shares at $68.4. February 25 '25 |
Similar companies
Read more about Biomarin Pharmaceutical (BMRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Biomarin Pharmaceutical?
The Market Cap of Biomarin Pharmaceutical is $10.2B.
What is Biomarin Pharmaceutical's PE Ratio?
As of today, Biomarin Pharmaceutical's PE (Price to Earnings) ratio is 15.66.
What is the current stock price of Biomarin Pharmaceutical?
Currently, the price of one share of Biomarin Pharmaceutical stock is $53.29.
How can I analyze the BMRN stock price chart for investment decisions?
The BMRN stock price chart above provides a comprehensive visual representation of Biomarin Pharmaceutical's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomarin Pharmaceutical shares. Our platform offers an up-to-date BMRN stock price chart, along with technical data analysis and alternative data insights.
Does BMRN offer dividends to its shareholders?
As of our latest update, Biomarin Pharmaceutical (BMRN) does not offer dividends to its shareholders. Investors interested in Biomarin Pharmaceutical should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biomarin Pharmaceutical?
Some of the similar stocks of Biomarin Pharmaceutical are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
